ZA927503B - Method for preventing allograft rejection. - Google Patents

Method for preventing allograft rejection.

Info

Publication number
ZA927503B
ZA927503B ZA927503A ZA927503A ZA927503B ZA 927503 B ZA927503 B ZA 927503B ZA 927503 A ZA927503 A ZA 927503A ZA 927503 A ZA927503 A ZA 927503A ZA 927503 B ZA927503 B ZA 927503B
Authority
ZA
South Africa
Prior art keywords
allograft rejection
preventing allograft
preventing
rejection
allograft
Prior art date
Application number
ZA927503A
Other languages
English (en)
Inventor
Mitsuaki Isobe
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of ZA927503B publication Critical patent/ZA927503B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA927503A 1991-10-01 1992-09-30 Method for preventing allograft rejection. ZA927503B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76804491A 1991-10-01 1991-10-01

Publications (1)

Publication Number Publication Date
ZA927503B true ZA927503B (en) 1993-05-03

Family

ID=25081356

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA927503A ZA927503B (en) 1991-10-01 1992-09-30 Method for preventing allograft rejection.

Country Status (8)

Country Link
EP (1) EP0610298A1 (xx)
JP (1) JPH07502727A (xx)
AU (1) AU667487B2 (xx)
CA (1) CA2120500A1 (xx)
HU (1) HUT69725A (xx)
MX (1) MX9205637A (xx)
WO (1) WO1993006864A1 (xx)
ZA (1) ZA927503B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
ES2103468T3 (es) * 1992-02-12 1997-09-16 Biogen Inc Tratamiento de la inflamacion intestinal.
ES2112431T3 (es) * 1992-08-21 1998-04-01 Genentech Inc Procedimiento para el tratamiento de un trastorno mediado por lfa-1.
US5817515A (en) * 1993-12-23 1998-10-06 Icos Corporation Human B2 integrin alpha subunit antibodies
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
AU2001230920A1 (en) * 2000-01-14 2001-07-24 Genentech Inc. Diagnosis and treatment of hepatic inflammatory disorders by inhibiting the binding of lfa-1 to icam-1
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
EP1419236A4 (en) 2001-07-24 2005-08-03 Biogen Idec Inc METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
US7662921B2 (en) 2004-05-07 2010-02-16 Astellas Us Llc Methods of treating viral disorders
MXPA06014354A (es) 2004-06-09 2007-02-19 Genentech Inc Metodo para tratar granuloma anular o sarcoide.
EP2102367A2 (en) 2006-11-09 2009-09-23 XDX, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3852374T2 (de) * 1987-11-02 1995-05-04 Baylor College Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
DE68929477T2 (de) * 1988-09-28 2004-06-03 Dana-Farber Cancer Institute, Boston Interzellulare Adhäsions-Moleküle und deren Bindungsliganden
AU636589B2 (en) * 1988-11-14 1993-05-06 Brigham And Women's Hospital Antibodies specific for elam-1 and the use thereof
ES2035668T3 (es) * 1989-03-09 1993-04-16 Boehringer Ingelheim Pharmaceuticals Inc. Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma.
ZA903223B (en) * 1989-04-28 1991-02-27 Baylor College Medicine Dissemination of hiv-1 infected cells
US5011778A (en) * 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
GB9009549D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method

Also Published As

Publication number Publication date
MX9205637A (es) 1993-05-01
JPH07502727A (ja) 1995-03-23
AU2782992A (en) 1993-05-03
HUT69725A (en) 1995-09-28
WO1993006864A1 (en) 1993-04-15
AU667487B2 (en) 1996-03-28
EP0610298A1 (en) 1994-08-17
CA2120500A1 (en) 1993-04-15
HU9400930D0 (en) 1994-06-28

Similar Documents

Publication Publication Date Title
ZA917163B (en) Filtration arrangement and method.
HK1010191A1 (en) Method for manufacturing anti-viral compounds.
EG19392A (en) Improved method for omprazole symthesis
EP0656319A3 (en) Process for the production of alumina-alpha powder.
EP0605240A3 (en) Automatic focusing device.
EP0568269A3 (en) Diode and manufacturing method.
EP0595233A3 (en) Process for the production of a semiconductor on insulator.
EP0625781A3 (en) Editing device.
ZA922313B (en) Anticoagulants and processes for preparing such.
EP0626410A3 (en) Process for the preparation of polycarbonates.
EP0592034A3 (en) Extensive statistical design method.
EP0604025A3 (en) Image forming method.
ZA927503B (en) Method for preventing allograft rejection.
EP0589725A3 (en) Heat-sensitive method for forming images.
ZA925463B (en) Method for the manufacture of tall oils.
EP0656067A4 (en) METHODS FOR SCREENING FOR IMMUNOSUPPRESSIVE AGENTS.
EP0578962A3 (en) Receptor identification procedure.
EP0646846A3 (en) Image forming method.
EP0585529A3 (de) Stützlager.
EP0607696A3 (en) Image processing method.
ZA93782B (en) Determination method.
AU2323492A (en) Method for inhibiting allograft rejection
EP0644805A1 (de) Automatische umformmaschine.
EP0599142A3 (de) Verfahren zur Herstellung von Immunkonjugaten.
EP0578138A3 (en) Gene detection method.